Skye Bioscience free cash flow SKYE

Cash from operations less capital spending, by quarter and over the last twelve months, from 2013.

Skye Bioscience's free cash flow was −$38.8M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$7.1M.

Free cash flow over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	Free cash flow	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$7.1M	n/a	−$38.8M
Q1 FY26	Mar 31, 2026	−$8.6M	n/a	−$42.4M
Q4 FY25	Dec 31, 2025	−$9.8M	n/a	−$43.1M
Q3 FY25	Sep 30, 2025	−$13.4M	n/a	−$41.5M
Q2 FY25	Jun 30, 2025	−$10.7M	n/a	−$34.9M
Q1 FY25	Mar 31, 2025	−$9.2M	n/a	−$31.3M
Q4 FY24	Dec 31, 2024	−$8.2M	n/a	−$26.8M
Q3 FY24	Sep 30, 2024	−$6.8M	n/a	−$22.5M
Q2 FY24	Jun 30, 2024	−$7.1M	n/a	−$19.7M
Q1 FY24	Mar 31, 2024	−$4.7M	n/a	−$14.6M
Q4 FY23	Dec 31, 2023	−$3.9M	n/a	−$14M
Q3 FY23	Sep 30, 2023	−$4.1M	n/a	−$15M

Companies in Healthcare nearest Skye Bioscience's size, closest first, today.

Company	Free cash flow yield
SKYESkye Bioscience	−569.2%
NEPHNephros	n/m
ATNMActinium Pharmaceuticals	n/m
APTAlpha Pro Tech	10.3%
SPROSpero Therapeutics	n/m
Peer median	10.3%

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.